Organization | Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals LLC Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Waltham MA United States (2003)

Organization Overview

First Clinical Trial

2009

NCT00827138

First Marketed Drug

2020

ripretinib

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Deciphera Pharmaceuticals LLC | DECIPHERA PHARMACEUTICALS LLC | DECIPHERA PHARMS

Active Ingredients

Marketed Drugs (1)

ripretinib (2020)

Drugs in Phase 3 Trials (3)

dcc-2618 (3 trials)

dcc-3014 (2 trials)

sunitinib (sutent) (1 trial)

Drugs in Phase 2 Trials (5)

binimetinib (mektovi) (1 trial)

carboplatin (paraplatin) (1 trial)

paclitaxel (taxol) (2 trials)

rebastinib (4 trials)

ripretinib (3 trials)

Drugs in Phase 1 Trials (5)

altiratinib (1 trial)

dcc-3116 (1 trial)

eribulin (halaven) (1 trial)

repaglinide (prandin) (1 trial)

trametinib (mekinist) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Gastrointestinal Stromal Tumors (Phase 3)

Giant Cell Tumor of Tendon Sheath (Phase 1)

Giant Cell Tumors (Phase 1)

Leukemia (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Mastocytosis (Phase 1)

Mastocytosis, Systemic (Phase 1)

Neoplasms (Phase 2)

Synovitis, Pigmented Villonodular (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 13